Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Suptavumab 30 mg/kg
Regeneron UK Limited
Respiratory Syncytial Virus Infections
1 trial -
Suspension of autologous mononuclear cells separated from bone marrow aspirate
The George Institute
diabetic foot syndrome, lower limb ischemia
1 trial -
Sutent 12.5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PAZOPANIB , Sutent 25 mg hard capsules
Incyte
Locally advanced/metastatic renal cell carcinoma
1 trial -
Sutent 50 mg hard capsules, Alectinib (Alecensa), Sutent 12.5 mg hard capsules, Cotellic, Sutent 25 mg hard capsules, RO7047650, Cotellic, Alecensa 150 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, Zelboraf, Sutent 12.5 mg hard capsules, Venclexta, Venclyxto, Alecensa 150 mg hard capsules, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, RO7250726, Sutent 25 mg hard capsules, ALIMTA 500 mg powder for concentrate for solution for infusion, Sutent 50 mg hard capsules, Ze
Hoffmann-La Roche
Advanced Malignancies
1 trial -
Suzhou Sceneray® DBS System
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Opiate Addiction
1 trial -
Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, BFF (PT009), BD ( PT008), SALBUTAMOL, Placebo MDI and empty TBH devices (only for training purposes)
AstraZeneca AB
Inadequately Controlled Asthma
1 trial -
Systematic oral health education
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Malignant Tumor of Head and/or Neck
1 trial -
TACROLIMUS, ALPN-303 solution for injection in pre-filled syringe, TACROLIMUS, TACROLIMUS, ALPN-303 solution for injection, Test IMP without active substance, ALPN-303 Solution for Injection in Pre-filled Pen
Vertex Pharmaceuticals (Australia) Pty.
Primary Membranous Nephropathy
1 trial -
TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Datopotamab deruxtecan
AstraZeneca AB
Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer
1 trial -
TAGRISSO 80 mg film-coated tablets, INFLIXIMAB, TAGRISSO 40 mg film-coated tablets, MYCOPHENOLATE MOFETIL, GLUCOSE, IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO
AstraZeneca AB
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO
AstraZeneca AB
Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo
AstraZeneca AB
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, placebo capsule G065, placebo capsule G040, JNJ-61186372, JNJ-73841937, JNJ-73841937-ZCY Placebo Oral Film-Coated Tablet
Janssen-Cilag International N.V.
EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
1 trial -
TAK-330
Takeda
Coagulation Disorder
1 trial -
TAK-438
Takeda
H. Pylori Infection
1 trial -
TAK-536
Takeda
Hypertension
1 trial -
TAK-536CCB
Takeda
Grade I or II Essential Hypertension
1 trial -
TAK-536TCH tablet
Takeda
Essential Hypertension
1 trial -
TAK-667
Takeda
Hereditary Angioedema
1 trial -
TAK-743 300 mg
Takeda
Hereditary Angioedema
1 trial -
TAK-816+ DPT-TAKEDA
Takeda
Immunization
1 trial -
TAK-881
Baxalta Innovations GmbH
Primary Immunodeficiency Diseases
1 trial -
TAK-881, HyQvia 100 mg/mL solution for infusion for subcutaneous use, HyQvia 100 mg/mL solution for infusion for subcutaneous use
Takeda
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources